136ｾ408 縺0106 ﾌ036ﾑ86ｾ4 ﾌ04 ﾇ 罔ﾐ6ﾑ86ｾ4 ｨB080ｸ ｧ90ｷ ｧ8 apple080ｸ7046ｧ ｦ001000ｷ ｹ ｧ9000ｹ ｧ9000ｹ0, 02

Transcription

1 136ｾ46ﾑ8096ﾒ26ﾑ ｦﾐ ﾌ6ｾ ﾒ20308apple08apple086ｧ ｷ fi07020ｷ307 ﾒ0607 6ｦ007080ｸ ﾞ ｧ90ｹ ｧ8 ﾞ apple apple080ｹ ｹ0*, 6ﾑ8apple6ｧ902080ｸ703080ｹ0 ﾒ ｧ80ｹ ｧ9 0ｹ0, ｦﾐ ｧ8 6ｾ ｧ apple ｧ9080ｸ7 ｦﾐ0ｷ ｧ9070ｷ ｹ ｹ0, 6ﾑ8apple6ｧ902080ｸ703080ｹ0 ﾒ ｧ80ｹ0 ﾞ ｸ ｧ80ｹ0, ｦﾐ ｧ8 6ｾ ｧ apple ｧ9080ｸ7 ｦﾐ0ｷ ｧ9070ｷ fi0308 apple ｧ apple ｧ8 apple ｧ ｧ8 07fi04080ｹ0 (09 ﾞ03) fi ｷ ｧ80ｹ ｧ9 0ｹ0 ｮ apple ｧ8 ｯ 07fi ｷ ｷ ｷ ｷ ｹ ｧ80ｹ ｧ80ｹ0. ﾌ ｹ0 00apple06apple fi0ｹ ｹ0 07fi04080ｸ applefi ｦ00ｹ0 apple ｹ0 020ｷ307 0ｸ7applefi 閨0209 apple ｸ , ｹ applefi 02060ｹ fi 080ｸ70ｹ ｹ ｷ304090ｹ0. 縺06 apple , 08 00apple06apple fi0ｹ ｹ0 09 ﾞ03 006ｧ apple ｹ ｸ70ｹ0 ﾞ ｧ80ｹ ｷ3096ｧ80ｹ0 ﾞ ｦ00ｹ ｦ ｸ70ｹ apple 07fi080ｷ307080ｸ70ｹ ｸ702086ｦ00ｹ0, fi0ｹ0 apple080ｸ7 00apple ｧ ｧ ｹ0 applefi ｦ apple6ｧ9- apple020ｷ30409 apple 03 09fi07020ｷ ｦ007080ｸ ｧ80ｹ0 07fi04080ｸ7 ( ﾒ ﾞ03), fiapple0ｷ30ｹ ｹ ｧ802090ｹ0, 09 0ｸ7apple 閨 apple 040ｸ ｧ9. [1] 縺 , ｸ70407fi ｹ0 07fi04080ｸ7 006ｧ ｦ ｸ70ｹ ｹ ｸ ｧ9. [1] ﾇ 09 ﾞ ｷ303006ｧ ｷ30ｹ ｧ8030ｷ ｹ0 040ｸ ｧ80ｹ ｸ ｧ80ｹ0 07fi04080ｸ7 apple080ｸ7 閨 ﾑ ｧ8 07fi04080ｹ ｧ fi- 070ｷ307. ﾌ 04080ｸ fi ｹ0 006ｧ ｹ0 ( ﾞ08ｦﾐ, ankle-brachial index) 閨 ｧ9 0ｷ30ｹ ｧ ｸ7 6ｧ ｧ8 00 閨 ｹ ｷ ｹ0 09 ﾞ ｷ303006ｧ ｧ ｹ ｸ700 閨07090ｹ ｷ ｷ304090ｹ0. [2] 0903fi 閨07 applefi apple ｧ ｧ8 REACH 00apple ｧ ｸ707 fi0206 apple fi applefi % 020ｷ ﾞ03 006ｧ 閨0ｹ ｧ ｹ ｧ9 0ｹ0 6ｧ ｧ80ｹ0 07fi04080ｸ7[3] (6ｾ4046ｧ8-00 1). 6ｾ fi0ｹ fi0ｹ0 020ｷ ﾞ03 apple 閨07080ｸ ｷ [4], fi apple fi ｷ3-00 閨 ﾞ apple000ｸ ｧ8 090ｷ3096ｧ apple ｹ0 apple080ｸ ｸ ｧ907-0ｸ ｹ ｸ ｷ307 [5, 6] ｸ ｧ ｧ ﾞ03 (6ｾ4046ｧ800 2) 6ｾ apple fi ｸ70ｹ ｧ90ｹ ﾞ03 006ｧ ｸ700apple020ｷ ｧ 閨02000ｹ0 陦 fi ｹ0 apple fi ｹ0 apple000306apple ｹ0 6ｾ ｧ9 07fi04080ｹ ｧ9apple080ｸ ｷ303fi apple ｧ9 006ｧ ｧ fi0708 閨 fi apple fi ｧ9- ｨB apple06 006ｧ9070ｷ ｹ0 040ｸ700apple020ｷ ｧ9 0ｹ0 020ｷ ｷ ｷ307 [5, 6]. 0903fi ｧ ｧ9 apple080ｸ ｧ apple ｾ4046ｧ ｾ40ｸ7076ｦ0apple ｷ ｷ ｹ ｷ ｧ80ｹ ｧ9 0ｹ ｧ80ｹ0 07fi04080ｸ7[3]. 00apple apple 03 閨 apple applefi ｸ7-00apple020ｷ ｷ ｧ90ｷ ｧ ｹ ｧ9 0ｹ ｸ 閨03080ｸ70ｹ0. 2. ﾇ 09 ﾞ03 0ｷ30ｹ ｦ ｧ9080ｸ ｦ007080ｸ7 ﾇ apple fi ｧ8030ｷ304090ｹ ｷ apple06apple ｧ ｸ 閨 ｸ70ｹ ｧ90ｹ ﾞ03. ﾌ 026ｧ907 0ｸ707080ｹ ｹ ｹ ｸ7 000ｸ ｧ9080ｸ7 006ｧ apple ｹ0, ｧ907 0ｸ ｹ ｦ ｦ0 00apple ｧ9080ｸ 閨0ｹ ｦ ｹ ｦ apple080ｸ 閨04080ｸ707 apple ｧ apple ﾌ ｧ90ｹ ﾞ 閨04080ｸ 閨0ｹ ｦ ｧ907 0ｸ ｸ ｧ80ｹ fi ｹ 閨0ｹ0 apple0608 0ｸ 閨 ｧ907-0ｸ fi ｹ ｧ9 0ｹ ｸ ｷ ｦ ｧ90ｹ0 apple080ｸ 閨04080ｸ ﾞ03 [1, 2, 9]. ﾌ 026ｧ907 0ｸ707080ｹ ｧ9ｨB ｹ ｦ0 040ｸ ｹ0 006ｧ ｹ0 applefi apple 03080ｸ7046ｧ9 6ｧ8 fi ｸ700apple020ｷ ｷ ｧ9apple080ｸ704 0ｹ0 040ｷ3-03fi ｹ ｧ ｸ 閨07080ｹ0 02fi ｹ0 apple000306apple ｹ ｷ3036ｧ90ｹ0 040ｸ700apple apple080ｸ ｸ7 ﾞ08ｦﾐ. ﾒ ｸ707 鐶pple0006, ｧ90ｹ ﾞ03 apple03 鐶pple ｷ3apple6ｧ9ｨB ｷ30ｹ ｧ90ｹ ｹ0 000ｸ ｦ00ｹ0 apple03fi ｹ0, fiapple0ｷ30ｹ ｧ90ｹ ｷ300 閨 ｧ9 07fi0408 [10] apple000ｸ ｧ8 apple 閨 ﾞ03 6ﾑ80202fi0ｹ0 applefi 02060ｹ0 apple000306apple ｹ0 020ｷ apple080ｸ7 apple03 鐶pple ｷ3apple ｦ007 00apple000609fi07020ｷ30ｹ0 applefi ｸ70309fi, fi0ｹ ｹ0 apple030ｷ ｦ00ｹ ｧ9 0ｹ ｧ apple 03 apple 閨00apple fi ｸ70309fi apple00036ｧ9apple020ｷ ｦ00ｹ ｧ8 020ｷ ｸ7-00apple020ｷ ｷ307 apple apple006ｧ9, apple080ｸ ｧ9-

2 136ｾ408 縺0106 ﾌ036ﾑ86ｾ4 ﾌ04 ﾇ 罔ﾐ6ﾑ86ｾ4 ｨB080ｸ ｧ90ｷ ｧ8 apple080ｸ7046ｧ ｦ001000ｷ ｹ ｧ9000ｹ ｧ9000ｹ0, ｹ fi03080ｸ70ｹ ｸ70ｹ ｧ90ｹ ｧ80209 [11] (096ｧ ｹ0 1). ﾇ 00apple ｧ8 apple 03 閨 apple08apple086ｧ ｷ307 apple 03 09fi07020ｷ ｦ ｦ007080ｸ7 apple080ｸ ｷ300 閨07 0ｸ ｸ ｧ907 0ｸ ﾞ03 006ｧ apple 閨 ] apple06 閨 ｧ80ｹ0[2, (6ｾ4046ｧ800 3) apple6ｧ ｸ7 02 apple076ｧ ｹ0 6ﾒ apple apple ｨB ｧ907-0ｸ ｹ0 09 ﾞ03, apple ｧ8 020ｷ ｸ7026ｧ apple06ｨB6ｧ ｸ7076ｧ ｸ7apple apple ｨB ｧ907 0ｸ apple06 006ｧ9070ｷ304090ｹ ｹ0 6ｧ8 09 0ｸ7apple ｸ704 0ｹ apple ｹ0[13] 0ｸ ｹ ｧ907-0ｸ ｧ8030ｷ304090ｹ ｧ80ｹ ｧ9 0ｹ ｸ 閨03080ｸ70ｹ0 6ｧ8/ ｷ ｦ0. 6ｾ 閨0209 apple ｧ ｹ 閨 ｸ70404 閨 ｸ7 02 apple076ｧ ｹ ｷ ｷ ｧ90ｹ ﾞ03 [14]. ﾞ07026ｧ , apple6ｧ ｸ7 02 apple076ｧ ｹ0 0ｸ apple066 56ｧ90ｷ30409 [15]. 縺 apple6ｧ ｸ7 02 apple076ｧ ｹ0 040ｸ ｸ ｧ8 020ｷ ｸ ｸ703000ｸ apple ｧ ｹ0 6ｧ8/ ｧ ｸ apple 03 09fi ｷ307, fiapple0ｷ30ｹ ｸ7apple03fiapple0608, 02 0ｸ7apple ｧ907090ｹ0, ｹ fi fiapple0ｷ30ｹ ｧ90709 [16] ﾞapplefi ｸ 閨0203, 09 6ｦ ｹ0 040ｷ ｧ80ｹ fi ｹ0 閨 apple ｧ9 fi ｸ700apple020ｷ ｧ9 020ｷ , apple fi 閨04080ｸ ｷ ｧ80ｹ ｧ9 - ｮ ﾞ 0ｸ ｧ9 ｯ ｷ304090ｹ0-040ｸ70404 閨 apple ｦ ﾑ ｧ8 040ｸ700apple020ｷ ｷ307 apple apple006ｧ ｧ90ｷ ｧ8 apple080ｸ7046ｧ ｦ001000ｷ ｹ ｧ9000ｹ ｧ9000ｹ0-6ｾ ｹ ｧ802090ｹ0 6ﾑ8apple006ｧ909080ｸ704 : - ﾒ036ｧ ｧ9 / 09fi07080ｹ apple 0ｸ ｹ0 6ｧ8 縺 apple086 76ｧ9 ﾞ ﾒ ﾞ / 6ﾒ2ｦﾐ ﾞ / Amaurosis Fugax 096ｧ ｹ0 1. ﾞ ﾞ ｸ ｧ80ｹ0 6ﾑ802026ｧ ｹ0 ﾞ ｧ8 ﾞ apple [2,9] ｹ ｧ90ｷ304090ｹ ｹ ｸ fi ｹ ｸ ｧ9080ｸ7, 02090ｹ ｧ90ｷ ｹ ｹ ｸ70ｹ ｧ9 0ｹ0, 02090ｹ0 000ｸ707080ｸ8026ｧ80ｹ0 00apple6ｧ ｹ fi 020ｷ ｸ ｸ70ｹ ｦ00ｹ0 apple ｹ0[17]. 6ｾ402060ｹ0 046ｦ ｹ0 040ｸ ｹ apple ｹ0 020ｷ ﾞ apple ｧ9 apple030ｷ fi 00 閨 apple 03 閨 ｹ0[2, 9]. 6ｾ402060ｹ ｸ7030ｸ707026ｧ ｹ ｧ9000ｹ0 040ｸ ｧ ｧ90200 閨07 apple03fi ｹ0 0ｸ7applefi 00apple6ｧ ｹ ｹ min, 02080ｸ 閨0ｹ apple fi ｹ0 applefi ｹ0 006ｧ fi apple03fi ｹ0 ( ) 040ｷ3036ｧ90ｹ0 00apple6ｧ ｸ 閨0ｹ ｾ ｸ apple 閨 閨 apple086ｧ9 040ｸ ｧ ｹ ｧ90ｹ ｸ700apple020ｷ ｧ8 09 ﾞ03, 00 閨04090ｹ ｧ9 0ｹ , fi ｧ90200 閨 閨0708 apple03fi apple6ｧ80ｹ ｸ7 02 apple076ｧ ｹ ｸ707 0ｸ7 0400fi ｦ ｷ ｧ80ｹ fi ｹ0 ( apple 03 閨 ｹ0, n=441) 006ｧ ｧ90ｹ0 08 閨 ｷ300 閨 ｧ ｸ ｦ ｦ0 ( 閨 ｸ7, n=441). 6ｾ46ｦ000080ｷ apple 閨 ｹ ｹ0, ｹ0 apple 03 閨 ｹ0 apple ｧ ｦ apple ｧ90ｷ304090ｹ ｹ0 00 閨 ｹ ｸ7fi ｹ0 applefi ｹ0 (maximum walking distance, apple fi ｧ90ｷ304090ｹ ｦ 閨 ｸ7 (23% vs 15%; P=0.008). ﾞ0ｸ702fi apple08 fi ｸ7036ｧ90ｷ30ｹ ｦ ｹ0 040ｷ ｧ80ｹ fi ｹ0 [34% 020ｷ ｹ0 apple 03 閨 ｹ0 apple0003apple 02086ｦ apple fi ｹ0 applefi 閨0ｹ vs 25% ｸ7 (P=0.01)]. ﾞ016ｧ9ｨB ｷ303006ｧ9 fi ｹ0 apple 03 閨 ｹ0 12% 020ｷ apple fi03030ｷ fi apple 閨 % 閨 ｸ7 (P=0.43) 3.3. ﾞ apple ｧ8 090ｷ3096ｧ ｹ fi0ｹ 陦 fi ｧ apple ｧ80ｹ0 090ｷ3096ｧ80ｹ0 (020ｸ7apple apple06-036ｧ90709) fi ｸ ｸ ｦ ｦ007080ｸ ｧ90ｹ ﾞ03. 6ｾ ｸ ｸ apple 閨070ｷ , apple080ｸ7 040ｸ700apple 閨 ｸ ｧ90ｹ ｸ700apple020ｷ ｧ8 09 ﾞ03, ｧ apple ｧ80ｹ0 090ｷ3096ｧ80ｹ0 040ｸ ｧ9ｨB ｧ90ｷ % 02080ｸ ｦ007080ｸ ｧ ｧ80ｹ fi ｹ ｦ ｧ ｦ ｸ7[19]. 6ｾ 閨0209 CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events), ｦ0 020ｷ ｸ700apple ｧ ｧ90ｹ ﾞ03, apple086ｧ ｸ apple08066ｧ ｧ apple06036ｧ90709 (325 mg/0900 閨03 ) 006ｧ apple 閨0309 ( ｷ ｧ8 020ｷ307 0ｸ7apple 閨0ｷ ｹ ｷ ｧ80ｹ ｧ907090ｹ0, 75 mg/0900 閨03 ). ﾇ post-hoc ｸ ｷ ﾞ03 陦 fi ｦ apple06036ｧ ｸ70ｹ ｧ90ｹ0 apple080ｸ7 apple6ｧ apple 閨0309 apple ｧ ｧ90ｷ % 02080ｸ ｦ ｦ007080ｸ ｹ ｹ ｸ7 000ｸ ｧ9-080ｸ7, ｦ ｦ ｦ0 00apple ｧ9080ｸ7 6ｧ fi- 030ｷ ｸ ｷ ｧ80ｹ ｧ9 0ｹ0 (P=0.0028). ﾇ 040ｸ ｧ apple06036ｧ907090ｹ apple 閨 ｦ00ｹ ｧ90ｹ apple apple03086ｦ00ｹ0 apple ｹ ｦ007080ｸ 閨 fi0206 0ｸ7apple0003 閨 ｧ90ｷ ｷ ｸ ｷ307, ｸ apple fi 020ｷ apple06apple [21]. ﾇ ｧ apple ｧ90ｹ ﾞ03 閨 ｸ707080ｸ8026ｧ8 00apple6ｧ fi ｷ ｸ ｷ307, 020ｷ apple 閨04000ｷ ｹ apple ｧ80ｹ0[22]. 6ｾ402080ｸ70ｹ ｧ90ｹ ﾞ03 apple ｧ ｧ apple06036ｧ907090ｹ0 75 mg-325 mg/0900 閨03 6ｧ apple 閨03090ｹ0 75 mg/0900 閨03. ﾇ 00apple ｧ ｸ ｸ7 apple03 鐶pple ｧ ｸ700 閨 ｸ700apple ｦ004000ｹ

3 13046ﾑ8 ﾒ6ﾑ ｦﾐ ﾌ6ｾ ｧ9apple080ｸ704 0ｹ0 040ｷ303fi ｹ ｸ7fi 閨0ｹ0 apple fi ｸ70ｹ ｹ 閨0ｹ0 apple fi ｹ0 090ｸ707 6ｧ902000ｹ ｦ ｸ70ｹ ｦ00ｹ ｧ90ｹ0[30]. 0300fi apple 閨07 00apple ｸ707 fi ｸ7apple ｧ9 閨04080ｸ707 06apple apple fi ｹ0 09 ﾞ03 [12]. 6ｾ4046ｧ ｸ ｧ ｧ ｹ0 apple ｧ80ｹ ｧ80ｹ0 07fi04080ｸ7[2,9] ｹ0, ｧ ｸ ｦ00ｹ fi ｹ0[2, 9] apple080306apple ｧ8 090ｷ3096ｧ8 6ﾑ8apple 閨0ｹ 閨02000ｹ0 陦 fi0206 0ｸ7apple ｧ8 040ｸ70404 閨 ｦ ｸ ｦ007080ｸ7 09 ﾞ ｷ307 00apple06apple 陦0ｷ ｹ ｧ80ｹ0, 02090ｹ0 LDL fi03090ｹ0, ｷ ｸ ｧ90ｷ ｧ ｦ0 09 ﾞ ｷ307 00apple06apple 陦0ｷ ｹ0 HDL fi03090ｹ ｦ ｹ ｧ80ｹ fi03090ｹ mg/dl ｧ907 0ｸ707080ｹ ｹ0 09 ﾞ03 0ｸ % - 10% [23], ｦ ｹ ｸ7 apple09036ｧ902080ｸ ｧ8/ HDL fi fi0ｹ0 026ｧ907 0ｸ ｹ0 09 ﾞ03 0ｸ % [13] apple applefi ｷ , ｧ90ｷ ｷ307 00apple06apple 陦0ｷ ｹ fi03090ｹ ｸ7apple080306apple ｧ ｸ ｧ ｧ8 apple ｸ ｦ0 006ｧ90400 apple ｧ9 fi ｧ8 00apple ｦ 閨 ｷ ｷ ｹ ｧ9000ｹ ｧ9000ｹ0[24] post-hoc ｸ ｷ307 apple ｷ ｹ 閨02090ｹ0 4S (Simvastatin Scandinavian Survival Study) 陦 fi ｧ ｧ907090ｹ ｧ9080ｸ70ｹ ｧ90ｹ ｸ7apple ｧ ｧ90ｷ % 陦 0ｹ0 6ｧ apple06 006ｧ9070ｷ30409 apple030800apple ｸ704 0ｹ ｧ9apple080ｸ704 0ｹ0 040ｷ303fi ｹ0[25] 閨07 applefi 閨0209 Heart Protection Study 陦 fi ｧ90ｹ ﾞN 0ｷ ｦ ｧ fi ｸ70ｹ ｧ90ｹ0 apple080ｸ7 閨04080ｸ ｸ7 006ｧ9 080ｸ70ｹ ｧ8 07fi0408 (00006ｧ90ｷ % 020ｷ ｨBfi070ｷ ｸ ｷ307), applefi 02 00apple6ｧ9- apple00 020ｷ apple06 6ｧ90ｷ applefi apple 03080ｸ7046ｧ ｧ80209 [26]. 6ｾ apple03fi ｹ 閨02000ｹ0 閨04080ｸ707 00apple ｧ8 03 閨 ｹ apple006ｧ9 0ｹ ｧ907000ｹ apple ﾞ ｸ7apple ｧ9 02fi ｧ90ｷ ｷ ｸ700apple020ｷ ｷ307 [27] fi ｦ ｹ0 040ｸ ｧ80ｹ0 00apple066 56ｧ90ｷ304090ｹ0[28]. ﾞ016ｧ9ｨB ｷ303006ｧ9 fi apple006ｧ ｧ ｸ70ｹ ｧ90ｹ ﾞ03 閨 ｸ ｸ8026ｧ8 00apple6ｧ ｸ70ｹ0 006ｧ ｹ ｹ ｧ80ｹ0, ｧ ｹ0 040ｸ ｹ ｹ0 C ｹ0 apple030ｷ302000ｹ107090ｹ0 (CRP). ﾞ0ｸ7026ｧ ｹ ｷ 閨 ｧ9 fi ｸ ｧ9- ｨB ｧ90ｷ ｹ0 040ｸ ｧ80ｹ fi ｹ ｦ ｹ ｦ ｹ0 040ｸ700apple020ｷ ｷ307 00apple066 56ｧ90ｷ ｹ0 0ｸ ｷ [28]. 00apple0ｷ30ｹ ｸ70ｹ ｧ90ｹ ｧ9 07fi0408, 026ｦ ｹ0 0402fi04080ｹ ｹ0 0ｸ7apple080306apple ｧ80ｹ0 090ｷ3096ｧ80ｹ0 006ｧ ｧ90ｷ ｷ307 00apple06apple 陦0ｷ ｹ0 LDL fi03090ｹ ｷ3 applefi 100 mg/dl 6ｧ ｷ3 applefi 70 mg/dl ｧ90ｹ apple08036ｦ0 0ｸ 閨 fi 026ｧ907 0ｸ70708 [29] ｹ ｹ0 0ｸ7apple 閨 ｹ0 ﾇ 040ｸ70404 閨 ｸ7apple 閨 ｹ ﾞ ｷ303006ｧ fi ｸ7036ｧ ｦ ｸ70404 閨 ﾞ ｧ80ｹ0 6ｧ ｧ9-0ｹ0 07fi04080ｸ7. 6ｾ 閨 ｸ7 Framingham, 09 0ｸ7apple 閨 apple08-006ｧ fi0206 0ｸ ｧ907 0ｸ ｸ7apple ｧ9 apple ｹ0 00apple ｦ apple ｦ ｸ70ｹ ｧ90ｹ ﾞ ｸ7046ｧ ｸ ｧ8 00apple6ｧ ｷ apple , fi0ｹ fi0ｹ ｦ004000ｷ307 閨 apple ｧ 閨 ｸ70ｹ apple ｸ7apple ﾞ03 [31]. 6ｾ 閨0209 ﾇ ﾌ066ﾑ8 (Heart Outcomes Prevention Evaluation), apple06apple03fi fi ｹ ｧ90ｷ ｷ ｸ ｷ307 applefi ｧ fi0ｹ ｷ ｧ ｸ apple ｦ0 0007ｨB6ｦ ｸ ｹ ｧ907090ｹ0 ( -096ﾑ8 ﾞ), 02090ｹ apple036ｧ903090ｹ0, 6ｧ ｧ fi 02fi ｸ70ｹ ｧ90ｹ ﾞ03 fi ｸ70ｹ ｧ90ｹ ｹ ｹ ｧ80ｹ0 07fi ｸ7[32]. 6ｾ 閨0209 0ｸ7026ｧ8 020ｸ apple08066ｧ ｧ90ｹ ﾞ03, ｸ70ｹ0 08apple086ｧ9080ｸ70ｹ ｧ apple036ｧ903090ｹ ｧ90ｷ % fi 026ｧ907 0ｸ ｹ ｧ ｹ fi ｹ0 applefi ｧ8 07fi0408 [32]. ﾌ fi ｹ ｸ7apple ｧ80ｹ0 090ｷ3096ｧ80ｹ ｧ9ｨB apple6ｧ ｸ apple06apple 陦0ｷ fi ｷ307 applefi 140/90 mmhg 6ｧ fi ｷ307 applefi 130/80 mmhg ｧ90ｹ ｧ fi ｧ8 07fi0408 [2, 9]. ﾇ ABCD (Appropriate Blood Pressure Control in Diabetics) 陦 fi ｧ apple ｧ80ｹ apple006ｧ9 0ｹ0 (0000 閨 ﾑ8 ﾞ, apple036ｧ90309, 6ｧ 閨 ｷ ｧ8 020ｷ ｦ0030ｷ ｧ9080ｸ7, apple6ｧ90709) apple6ｧ902000ｸ ｷ fi040ｷ ｹ ｸ7apple ｧ80ｹ0 090ｷ3096ｧ80ｹ ｧ ｧ8 040ｸ70404 閨 ｦ ｸ7 ﾞ08ｦﾐ ｸ ｦ007080ｸ ｹ ｧ ｹ fi ｹ0 applefi

4 136ｾ408 縺0106 ﾌ036ﾑ86ｾ4 ﾌ04 ﾇ 罔ﾐ6ﾑ86ｾ4 6ｾ fi0ｹ0 ﾒ6ｧ907 0ｸ707080ｹ0 (RR) 6ｾ4046ｧ ｹ ｦ007080ｸ ｧ80ｹ0 ﾞ apple ｹ0 ｨC 閨07 6ﾑ8apple [5] ｧ8 07fi ｸ70ｹ ｧ90ｹ ﾞ03 [33] ｹ ｹ ｸ ｧ9 0ｹ 閨 apple ｧ ｹ0 陦 fi apple 03080ｸ7046ｧ ｧ ｸ ｧ907 0ｸ ｹ0 09 ﾞ ｧ ｷ300 閨07080ｸ70ｹ0 (07070ｷ3 020ｷ fi070ｷ307) 02 apple 閨0ｹ ｸ7apple 閨 ｸ7apple ｧ9 [12, 23] 閨 apple ｧ ｧ fi apple ｧ apple ｸ ｧ ｦ0- apple080ｸ ｦ0apple080ｸ ｧ907 0ｸ ｸ ｷ ｧ90ｹ0 09 ﾞ03 [34, 35] fi0408, 0400 fi03080ｸ70ｹ ｸ70ｹ ｦ00ｹ ｧ90ｹ0 040ｸ ｧ ｹ ｸ70208ｨB0ｸ703060ｷ300 閨07090ｹ ｧ907090ｹ0 (HbA1C) apple6ｧ9- apple fi applefi 7%, ｹ ｧ ｧ9 020ｷ ｷ307 apple ｧ90ｷ ｸ ｦ007080ｸ ｹ , ｹ ｹ fi ｹ ｷ ｦ0 [2, 9] apple000ｸ 閨0203 6ｾ400 fi03080ｸ70ｹ ｸ70ｹ0 0ｸ7apple 閨 ｸ70ｹ0 6ｧ8 apple 046ｦ ｸ70ｹ ｧ90ｹ ﾞ03 6ｧ ｸ ｸ703 閨0ｹ 閨 ｸ7 040ｷ ｦ ｸ70ｹ0. ﾞ070206apple ｧ8 090ｷ3096ｧ8 applefi 02080ｸ7 0402fi ｹ0 040ｸ fi ｹ0 apple apple ｹ apple06026ｧ ｸ7096ｧ8, apple , ｷ fi006 50ｷ30409, ｹ ｧ90ｹ0 0ｸ ｦ ｦ007080ｸ7 applefi ｹ0 020ｷ ｸ ｷ ｸ7apple ｸ707 apple030808apple 閨0ｹ0, 020ｸ apple 閨07000ｹ 閨02090ｹ ｧ ｹ ｸ 閨03080ｸ70ｹ ｧ ｹ , fiapple0ｷ30ｹ ｸ fi 08016ｦ ｧ apple080ｸ ｸ apple6ｧ9apple ｹ ｸ ｹ107090ｹ fi, ｧ90ｹ ﾞ03. 6ｾ 閨03080ｸ 閨 ｧ9 Health Professionals Follow-up Study, 040ｸ ｧ ｹ0 040ｷ3036ｧ90ｹ0 09 ﾞ03, ｧ8 07fi0408 6ｧ ｧ apple ｸ7036ｧ fi ｷ307 08apple086ｧ90ｷ apple000306apple ｹ0 09 ﾞ03. 6ｾ 閨0209 0ｸ7026ｧ8 06 apple ｧ ｸ70404 閨 ｦ ｹ ｧ80ｹ0 apple03fi ｹ0 080ｸ ｦ 閨080ｹ0 (400 mg/0900 閨03 ) ｸ ｦ007080ｸ ｹ0 09 ﾞ03 (00006ｧ90ｷ %) [36] ｧ90ｷ ｸ ｦ ｦ007080ｸ ｧ90ｹ ﾞ03: ｧ ｸ7 040ｸ ｦ ｦ007080ｸ apple ｧ ｧ apple000ｸ 閨02030ｷ apple ｧ ｧ apple ﾞ03 00apple 閨 ｷ30409, ｧ ｸ7 040ｸ ｦ ｦ007080ｸ apple ｧ8 apple 03 閨 apple08apple086ｧ ｷ307 apple 03 09fi07020ｷ ｦ007080ｸ7[2, 9]. 08apple ｸ ｧ ｹ0 fi apple ｧ apple08apple086ｧ ｷ307 apple 03 09fi ｷ ｦ007080ｸ ｧ90ｹ ﾞ03 apple ｹ0, ｦ ｦ0 00apple ｧ9080ｸ ｧ907 0ｸ fi030ｷ ｸ ｷ307. 6ｾ apple03fi 閨 ﾞ03, ｹ , 閨 fi apple006ｧ apple06036ｧ90709, ｧ907000ｹ0, 6 5- apple 閨0ｹ ﾑ8 ﾞ 040ｸ ｧ9ｨB ｦ ｹ0 00apple066 56ｧ90ｷ304090ｹ0[37]. 6ﾒ2 000ｸ7036ｧ ｸ ｸ ｦ fi apple08030ｸ apple006ｧ ｸ707-0ｸ7 0400fi ｧ8 0ｸ ｸ 閨02030ｷ307 ( , apple6ｧ ｸ7 02 apple076ｧ ｹ0, 00006ｧ90ｷ ｸ7 040ｷ ｦ ｸ70ｹ0) 閨 fi fi ｹ ｧ90ｷ ｸ ｦ ｦ007080ｸ fi ｷ ﾞ ｧ9 [1] Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, Circulation 2004; 110: [2] Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e [3] Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Jama 2006; 295: [4] Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol 2002;13:7-11. [5] Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. Jama 2001;286: [6] Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW, Jr. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41: [7] McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. Jama 2001;286: [8] McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. Jama 2004;292:

5 13046ﾑ8 ﾒ6ﾑ ｦﾐ ﾌ6ｾ [9] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter- Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1-75. [10] Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001;285: [11] Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ (Clinical research ed 2003;326: [12] Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: results for the National Health and Nutritional Survey, J Vasc Surg 2006; 44:319-24; discussion [13] Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006;113: [14] Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta chirurgica Scandinavica 1988;154: [15] Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. The Medical journal of Australia 1983; 1: [16] Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. The New England journal of medicine 2002;346: [17] Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. The New England journal of medicine 2002;347: [18] Fowler B, Jamrozik K, Norman P, Allen Y, Wilkinson E. Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial. The Australian journal of physiotherapy 2002; 48: [19] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed 2002;324: [20] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348: [21] Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England journal of medicine 2006;354: [22] Collaborative overview of randomised trials of antiplatelet therapy--ii: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ (Clinical research ed 1994;308: [23] Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-9. [24] Leng GC, Price JF, Jepson RG. Lipidlowering for lower limb atherosclerosis. Cochrane database of systematic reviews (Online) 2000;CD [25] Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). The American journal of cardiology 1998;81: [26] Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: [27] Giri J, McDermott MM, Greenland P, Guralnik JM, Criqui MH, Liu K, et al. Statin use and functional decline in patients with and without peripheral arterial disease. Journal of the American College of Cardiology 2006;47: [28] Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. European heart journal 2004;25: [29] Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110: [30] Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. Journal of the American Geriatrics Society 1985;33:13-8. [31] Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Archives of internal medicine 1991;151: [32] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England journal of medicine 2000; 342: [33] Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107: [34] Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. The American journal of cardiology 1995;75: [35] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: [36] Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. The Journal of nutrition 2003;133: [37] Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. Journal of the American College of Cardiology 2006;47: